Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/30/14
End: 06/30/16
Due: 06/30/17
Phase: N/A
Priority: Normal
Start: 08/31/15
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 10/31/15
End: 12/31/16
Due: 12/31/17
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia | NCT02250105 | Arisaph Pharmaceuticals Inc | user2@example.com | None | 2014-09-30 | 2016-06-30 | 2017-06-30 | - | - | 2025-07-14 |
| Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia | NCT02532218 | Arisaph Pharmaceuticals Inc | user2@example.com | None | 2015-08-31 | 2016-12-31 | 2017-12-31 | - | - | 2025-07-14 |
| A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis | NCT02574325 | Arisaph Pharmaceuticals Inc | user2@example.com | None | 2015-10-31 | 2016-12-31 | 2017-12-31 | - | - | 2025-07-14 |